| Business Summary | | Genset
is
an
integrated
genomics
company.
The
Company's
mission
is
to
discover
and
license
genomics
information
relevant
for
the
discovery,
development
and
marketing
of
new
therapeutics
for
common
diseases.
The
Company
has
developed
an
original
approach
to
the
discovery
of
important
genes,
based
on
association
studies
in
human
populations.
These
studies
are
made
possible
by
the
Company's
technology
platform,
which
integrates
key
scientific
tools
that
the
Company
has
either
invented
or
applied
in
novel
ways.
The
Company's
strategy
is
to
focus
its
research
efforts
in
the
following
fields:
central
nervous
system
diseases;
metabolic
disorders,
and
in
particular
obesity;
and
pharmacogenomics,
which
is
the
application
of
genomics
technologies
to
the
identification
and
analysis
of
genes
involved
in
drug
response. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Genset
is
a
fully
integrated
genomics
company
engaged
in
assisting
pharmaceutical
companies
in
the
discovery,
development
and
marketing
of
their
drugs
through
the
discovery
and
analysis
of
common
disease
and
drug
response
genes.
For
the
six
months
ended
6/01,
revenues
decreased
44%
to
EUR9.8
million.
Net
loss
totalled
EUR29.4
million,
up
from
EUR13.6
million.
Results
reflect
decreased
product
sales,
and
EUR7.6
million
in
non-recurring
charges. | More
from
Market Guide: Significant
Developments |
| Officers | |
| Position | Pascal Brandys, 41 | Chairman
and CEO | John Varian, 41 | CFO | Daniel Cohen, M.D., Ph.D., 49 | Director
and CGO | Marc Vasseur, Ph.D., 50 | Director
and CBO | Philippe Rousseau, 29 | VP-Fin. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|